Cynata Therapeutics
Business Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 Cubitt St L 3, Cremorne, Victoria, 3...Phone Number
+61 370676940Website
www.cynata.comRevenue
<$5 MillionStock Symbol
CYPIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cynata Therapeutics
Cynata Therapeutics specializes in regenerative medicine utilizing its proprietary Cymerus Platform, which focuses on the development of therapeutic products derived from mesenchymal stem cells. The company is engaged in clinical and pre-clinical development, offering a pipeline of innovative treatments aimed at addressing various medical conditions. Its intended clients include investors and stakeholders in the biotechnology sector, along with healthcare providers seeking advanced therapeutic solutions. Cynata is committed to advancing its technology and expanding its intellectual property through significant scientific research and publications.Explore more
Cynata Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cynata Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Cynata Therapeutics is spiking on competitors!
Click to see if Cynata Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cynata Therapeutics
Product Launch: Get notified when Cynata Therapeutics launches new products
Funding: Get notified immidiatlly once Cynata Therapeutics has new funding data
Check if Cynata Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Cynata Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cynata Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Cynata Therapeutics
Find more new buyers
Compare Similar Companies to Cynata Therapeutics
Compare insights from companies similar to Cynata Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cynata Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cynata Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cynata Therapeutics.
Cynata Therapeutics financials insights
Gather financial insights about Cynata Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$15M
Cynata Therapeutics Tech Stack
A closer look at the technologies used by Cynata Therapeutics
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Cynata Therapeutics has completed the first cohort in the kidney transplant trial, which was reviewed by an independent DSMB, and is now progressing to the second cohort of patients.
Partnership, Medical Research, Clinical Operations
Earnings
Earnings, Business Finance, Finance, Financial Operations
Cynata Therapeutics News & Media
Cynata capital raise as it prepares for pivotal clinical trial readouts - Biotech Dispatch
The cash injection is intended to strengthen Cynata’s runway through two near-term clinical milestones and to position the company for commercial partnering and regulatory engagement after results are released.Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease February...Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus...Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Q4 2025 Earnings Conference Call August 4, 2025 9:00 PM ETCompany ParticipantsKilian Kelly - MD, CEO &...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Cynata Therapeutics
Sign Up For FreeTo access detailed company insights
Cynata Therapeutics specializes in regenerative medicine utilizing its proprietary Cymerus Platform, which focuses on the development of therapeutic products derived from mesenchymal stem cells. The company is engaged in clinical and pre-clinical development, offering a pipeline of innovative treatments aimed at addressing various medical condition... Read More
